ハイコンテント分析のための創薬ツール

Abstract

The area of drug discovery tools is one of the newest and most important sectors of pharmaceutical research and development. The term drug discovery tools usually refers to high-content screening (HCS) and analysis and is composed of those applications that require sufficient levels of sample throughput, whereby complex cellular events and phenotypes can be studied. Elements of drug performance like toxicity and specificity can be established simultaneously using mixed cell types-primary cells, cell lines, cell subpopulations. HCS seeks to assess the impact of phenotypic and cellular changes that are brought about by gene modification (such as with RNA interference (RNAi) approaches) and/or drug (or compound) treatment. The purpose of this examination by TriMark Publications is to describe the specific segments of the global drug discovery tools market. Within this area, the report covers those segments that are highly active in terms of innovation and growth. Specifically, this study examines the markets for small lab equipment all the way up to highly automated, large automated platforms, as well as accessory equipment such as reagents, supplies and manufacturers' original equipment manufacturer (OEM) additional equipment.

Table of Contents

1. Overview

• 1.1 Objectives of the Report
• 1.2 Methodology
• 1.3 Scope of the Report
• 1.4 Executive Summary

2. Technologies and Product Offering for HCA

• 2.1 Definition of HCA and Why it is so Attractive a Discipline
• 2.2 Classes of Measurements Possible with HCA Approaches and Biologies Interrogated
• 2.3 Instrumentation Platforms for HCA
• 2.4 Reagent and Assay Platforms for HCA
• 2.5 Cell-based Screening Technologies in Drug Development
  • 2.5.1 Applications of Cell-based Assays
  • 2.5.2 Pharma Drug Discovery Paradigm and Compound Screening
  • 2.5.3 HCA in the Biopharmaceutical Industry

3. Market Analysis of the High-Content Tools Space

• 3.1 HCA Market Size and Growth
• 3.2 Market Survey to Assess Qualitative and Quantitative Parameters of the HCA Space
• 3.3 Experimental and Research Trends in HCA
• 3.4 Challenges and Market Drivers in HCA
  • 3.4.1 Barriers to HCA
  • 3.4.2 Drivers of HCA
• 3.5 HCA in Combination with RNAi
• 3.6 Market Landscape of Instrumentation for HCA
• 3.7 Reagents and Assays Usage in HCA
• 3.8 Trends in HCA Assays/Reagents Space-Major Product Vendors
• 3.9 Emerging Market Trends in HCA
• 3.10 Market Forecasts for the HCA Space
• 3.11 Use of HCS in Pharmaceutical Companies
• 3.12 Qualitative Opportunities and Challenges for Market Adoption

4. Strategic Analysis of the High-Content Tools Space

• 4.1 HCA Market Structure
• 4.2 Description of the Drug Discovery Marketplace and Definition of the Field
• 4.3 Key Market Drivers and Challenges in the HCA Space
• 4.4 Consolidated Picture of the HCA Marketplace
• 4.5 HCA Market Sectors and Growth Rate
• 4.6 Vendors of HCA Technology

5. HCA Technology Platforms

• 5.1 Methods of Digital Imaging
• 5.2 Fluorescence Microscopy
• 5.3 Major HCA Instrumentation
• 5.4 HCA Reagents
• 5.5 Imaging Software
• 5.6 Image Analysis Algorithms
• 5.7 Use of RNAi in HCA
• 5.8 Industry Alliance to Leverage RNAi and HCA
• 5.9 Emerging Trends in HCA Technology Platforms

6. HCA in Drug Selection and Screening

• 6.1 Stem Cells Used as a Drug Discovery Tool
• 6.2 Drug Discovery Companies Marketing Cell-based Assays

7. Company Profiles and Glossary of Terms in HCA

• 7.1 Acumen Pharmaceuticals, Inc.
• 7.2 Applied Biosystems
• 7.3 Becton, Dickinson and Company
• 7.4 Beckman Coulter, Inc.
• 7.5 Blueshift Biotechnologies, Inc.
• 7.6 Caden Biosciences, Inc.
• 7.7 Cellomics, Inc.
• 7.8 Cellumen, Inc.
• 7.9 Cenix BioScience
• 7.10 Cyntellect
• 7.11 Definiens
• 7.12 DiscoveRx
• 7.13 Euroscreen
• 7.14 Evotec Technologies
• 7.15 Fisher BioImage
• 7.16 General Electric
• 7.17 Guava Technologies, Inc.
• 7.18 Millipore
• 7.19 Molecular Devices Corporation
• 7.20 NIH Chemical Genomics Center
• 7.21 PerkinElmer
• 7.22 Spotfire
• 7.23 Translational Genomics Research Institute
• 7.24 Vala Sciences, Inc.

8. Glossary of Terms in the HCA Space

LIST OF FIGURES

• Figure 2.1: Scope of Biological Parameters Addressed via a Typical HCA Experiment
• Figure 2.2: Classes of Assays in Life Science Research and Drug Discovery Illustrating the Relationship between Cell-based Assays and HCA
• Figure 2.3: New Paradigm of Drug Discovery and Development Illustrating the Central and Essential Role of Screening
• Figure 2.4: Cumulative and New Drug Targets
• Figure 3.1: Breakout of Market Survey Respondents by Geographical Location
• Figure 3.2: Breakout of Market Survey Respondents by Affiliation-Academic, Commercial, Vendor
• Figure 3.3: Segmentation of Respondent Pool based upon Usage of HCA in its Research Activities
• Figure 3.4: Segmentation of the Survey Respondent Pool based upon the Length of Time they have been Using HCA in their Research Activities
• Figure 3.5: Number of Parameters Studied Simultaneously in HCA Assays-Multivariate (Multi-Parameter) Analyses
• Figure 3.6: Key Biological Processes Studied Utilizing HCA Tools
• Figure 3.7: Breakout of HCA Assays Currently Performed or Expected to be Performed in the Future by Biological Pathway (or Target)
• Figure 3.8: Breakout of HCA Experiments Performed Per Week (Distributed in our Respondent Pool) Across the Various Biological Pathways (and Targets)
• Figure 3.9: Which of the Biologies (Pathways/Targets) Addressed Using HCA-based Approaches are Growing in Importance or Declining?
• Figure 3.10: In Which Environment are HCA Assays Performed-Primary Screen, Secondary Screen, ADME/Tox Screen?
• Figure 3.11: Key Challenges Faced by the Research Community in Their Practice of HCA
• Figure 3.12: Various Drivers that are Leading the Research Community to Perform HCA
• Figure 3.13: HCA Together with RNAi-Current and Future Experimental Formats
• Figure 3.14: HCA Together with RNAi-Number of Experiments Performed Per Month by the Survey Respondent Pool
• Figure 3.15: Growing and Steady Usage of the Various Formats where RNAi is coupled with HCA
• Figure 3.16: Penetration of the Different HCA Instrumentation Platforms into the Marketplace
• Figure 3.17: Instrumentation Platforms for HCA Ranked by Top Choice and Second Tier
• Figure 3.18: HCA Instrumentation and where they lie on the Throughput Curve
• Figure 3.19: Top Instrumentation Value Drivers in the HCA Space
• Figure 3.20: Important Sub-Cellular Features Studied via HCA Approaches
• Figure 3.21: Breakout of End-Point versus Kinetic Assays in the HCA Space
• Figure 3.22: Types of Cellular Targets Studied Using HCA Approaches
• Figure 3.23: Top-most Target Class Being Studied Utilizing HCA Approaches
• Figure 3.24: Distribution of HCA Experiments across the Respondent Pool-Number of Experiments Performed Per Week
• Figure 3.25: Average Reagent/Assay Costs Per HCA Experiment
• Figure 3.26: Stratification of Reagent/Assay Suppliers into the HCA Space
• Figure 3.27: Monthly Reagent/Assay Purchases for HCA by the End-User Community from the Various Vendors Offering Products into the Space
• Figure 3.28: Growth or Decline in Importance of the Various HCA Vendors to the End-User Community
• Figure 3.29: Percentage of HCA Experiments that Involve GFP across the Market Landscape
• Figure 3.30: Breakout of HCA Reagents Marketplace: Home-Brew Versus Off-the-Shelf
• Figure 3.31: Breakout of Spending into the Various Components of the HCA Discipline
• Figure 3.32: Forecast Growth of the Total Screening Space-Broken-out by Primary Screening, Secondary Screening (Includes HCA as a Subset) and ADME/Tox
• Figure 3.33: Forecast Growth of the Screening Space-Broken-out by Cell-based Assays and Biochemical Assays
• Figure 4.1: Drug Discovery and Development Ensemble and the Position of the Various Segments of HCA in the Space
• Figure 4.2: Relative Size and Position of the HCA Space in the Overall Scheme of the Life Science Tools Marketplace
• Figure 5.1: HCA: Positional Biosensors Using Caspases and Monitoring the Translocation of a Tagged Protein from the Cytoplasm to the Nucleus
• Figure 6.1: Druggability of the Various Target Classes: Breakout of the Drug Targets Today into their Constituent Classes
• Figure 6.2: GPCR Assay Technologies

LIST OF TABLES

• Table 2.1: Comparison of the Key Features of HCA and HCS
• Table 2.2: Impact of HCA on Drug Discovery-Several Drivers are Addressed
• Table 2.3: Biological Application Areas Associated with HCA
• Table 2.4: Classes of Measurements and Targets Identified Using Phenotypic Screening (HCA)
• Table 2.5: Classes of Cellular Measurements Possible with Fluorescent Protein Biosensors
• Table 2.6: Multi-Parameter HCA Assays to Study Biological Systems in Life Science Research and Drug Discovery-Demonstrates the Breadth and Scalability of the HCA Approach
• Table 2.7: Companies Offering Systems for High-Throughput Imaging
• Table 2.8: Comparison of the Major Instrumentation Platforms and their Associated Specifications for HCA-I
• Table 2.9: Comparison of the Major Instrumentation Platforms and their Associated Specifications for HCA-II
• Table 2.10: Price Points and Target Markets of the Various HCA Instrument Platforms
• Table 2.11: Companies Offering Flow Cytometry Products and Services
• Table 2.12: Integrated Product Platforms Offered by the Different HCA Vendors
• Table 2.13: Biologies interrogated by Cellomics HCA Assays
• Table 2.14: Cellomics HitKit® HCA Assay/Reagent Kits and the Therapeutic Areas Where They Find Application
• Table 2.15: Assay/Reagent Portfolio of Millipore Addressing HCA Applications
• Table 2.16: Cell Lines for GPCR HCA that can be Deployed onto the BD Biosciences/Atto Pathway HT™ Instrument Platform
• Table 2.17: Examples of High Content Screens
• Table 3.1: What Fraction of HCA Assays are Cell-based Versus Biochemical-based
• Table 4.1: Comparison of the Key Features of HCA and HCS
• Table 4.2: Snapshot of the Various HCA Assays Demonstrating the Scalability of this Discipline
• Table 5.1: Modes of Digital Imaging
• Table 5.2: Modes of Fluorescence
• Table 5.3: Major HCA Instrumentation
• Table 5.4: Image Analysis Algorithms

ご注意：当報告書はDRM（デジタル著作権管理システム）付PDFとなります。ご購入頂いた場合、専用のビューアー（ご購入時無償配布）をPCにインストールして頂き、そのビューアーによってのみPDFの閲覧が可能となります。ファイルのコピー及び内容の抽出は出来ませんのでご注意下さい。尚、プリントアウトは何回でも可能です。ご不明な点につきましてはお問合せください。